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Abstract
Context
Permanent childhood hearing loss (PCHL) can affect speech, language, and wider out-
comes. Adverse effects are mitigated through universal newborn hearing screening (UNHS)
and early intervention.
Objective
We undertook a systematic review and meta-analysis to estimate prevalence of UNHS-
detected PCHL (bilateral loss�26 dB HL) and its variation by admission to neonatal inten-
sive care unit (NICU). A secondary objective was to report UNHS programme performance
(PROSPERO: CRD42016051267).
Data sources
Multiple electronic databases were interrogated in January 2017, with further reports identi-
fied from article citations and unpublished literature (November 2017).
Study selection
UNHS reports from very highly-developed (VHD) countries with relevant prevalence and
performance data; no language or date restrictions.
Data extraction
Three reviewers independently extracted data and assessed quality.
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Results
We identified 41 eligible reports from 32 study populations (1799863 screened infants) in
6195 non-duplicate references. Pooled UNHS-detected PCHL prevalence was 1.1 per 1000
screened children (95% confidence interval [CI]: 0.9, 1.3; I2 = 89.2%). This was 6.9 times
(95% CI: 3.8, 12.5) higher among those admitted to NICU. Smaller studies were significantly
associated with higher prevalences (Egger’s test: p = 0.02). Sensitivity and specificity ran-
ged from 89–100% and 92–100% respectively, positive predictive values from 2–84%, with
all negative predictive values 100%.
Limitations
Results are generalisable to VHD countries only. Estimates and inferences were limited by
available data.
Conclusions
In VHD countries, 1 per 1000 screened newborns require referral to clinical services for
PCHL. Prevalence is higher in those admitted to NICU. Improved reporting would support
further examination of screen performance and child demographics.
Introduction
Universal newborn hearing screening (UNHS) programmes enable prompt detection and
intervention for early-onset permanent childhood hearing loss (PCHL). This facilitates
improved speech and language development, as well as better health, educational and social
outcomes [1, 2]. Most very highly-developed (VHD) countries [3] have now implemented
UNHS programmes, defined as universal screening by age 6 months with otoacoustic emis-
sions (OAE) tests, auditory brainstem response (ABR) tests, or both, followed by diagnostic
referral where indicated [4].
Implemented programmes vary in size, programme quality, performance, and reported
prevalence of PCHL. The latter may be attributable to differences in type, timing, and fre-
quency of test procedures, referral criteria, diagnostic case definition, and management of at-
risk children (usually defined according to Joint Committee on Infant Hearing [JCIH] criteria
[1] or by neonatal intensive care unit [NICU] admission) [4–8]. Methods of follow-up to
ascertain PCHL among those with negative screening results (i.e. children that are not referred
to diagnostic testing) can also play an important role (for example, targeted surveillance or
subsequent screening).
Previous reviews of UNHS programmes have evaluated screening test methods or quality,
and timing of intervention after PCHL diagnosis [9–11]. There has been little quantitative syn-
thesis of PCHL prevalence or analysis of heterogeneity, particularly relating to demographic
and individual differences in the populations screened. Additionally, performance of entire
UNHS programme pathways as oppose to single tests (relating to measures of accuracy includ-
ing sensitivity, specificity, negative predictive value, and positive predictive value) have not
been systematically examined. Addressing these research gaps will inform screening policy
and improve service planning for children with PCHL, by enabling evaluation of UNHS pro-
grammes in respect to key indicators and benchmarks. Estimating the prevalence of PCHL
detected through UNHS also permits examination of secular trends and heterogeneity in
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terms of population and UNHS programme characteristics. This provides vital information on
UNHS programme performance and the effectiveness of PCHL prevention efforts.
We carried out a systematic review and meta-analysis to estimate the prevalence of PCHL
(defined as bilateral PCHL�26 dB HL confirmed by diagnostic tests) detected through UNHS
in VHD countries. Our secondary objectives were to examine how detected PCHL prevalence
varies between studies and by demographic characteristics, as well as to estimate UNHS pro-
gramme performance.
Methods
The review was carried out in accordance with the registered PROSPERO protocol
(CRD42016051267) and reported following MOOSE (S1 Table) and PRISMA (S2 Table)
guidelines.
Search strategy
To identify eligible studies, in January 2017 one reviewer (EB) interrogated electronic data-
bases (PubMed, Medline(OvidSP), EMBASE, CINAHL, and the Cochrane Library) and
reviewed the first 100 Google Scholar search results. Further reports were identified from cita-
tions of included papers and unpublished literature (November 2017). Text-word searches,
along with MeSH terms or Subject Headings, were used to construct database searches. Key
text-words related to: hearing loss, hearing impairment, deafness, epidemiology, incidence,
prevalence, and newborn, neonatal, child, infant, etc. (S1 File). There were no date or language
restrictions; all published reports were considered for inclusion if there was an English
abstract. Searches of unpublished literature included relevant screening programme reports in
any language, whether or not they had English abstracts.
PCHL definition
The review case definition for PCHL was bilateral PCHL�26 dB HL. This reflects the mini-
mum severity of PCHL defined by WHO that is expected to require long-term active manage-
ment [12] and excludes temporary conditions. Although milder (15–26 dB HL) and unilateral
PCHL can also impact on outcomes [13], these were not included as they are not always
detected, or systematically reported, by UNHS programmes. Acquired, progressive or late-
onset conditions were not included as UNHS does not capture these.
Inclusion and exclusion criteria
We included reports of programmes from VHD countries as defined by the United Nations
Development Programme (UNDP), such as the United Kingdom, United States, and Ger-
many, [3], as these are similar to each other in terms of UNHS provision, access to health care,
and child health and socioeconomic conditions. Studies were included if an English abstract
was available (not applicable to unpublished reports), UNHS was in place during the study,
and the total number of children with UNHS-detected PCHL fitting the review case definition
was reported, as well as the total number considered for, or undergoing, UNHS.
Studies were excluded if any inclusion criteria were not met, the minimum threshold for
PCHL exceeded 61 dB HL, they were an ineligible study or article type (review without a sys-
tematic search strategy, comment piece, letter, or editorial), there was evidence of ascertain-
ment bias, or all participants were aged over 1 year by study start (as UNHS should occur
before age 6 months). As the aim was to estimate population-based prevalence, studies
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involving a selective sample of children considered to be at high-risk of PCHL were excluded,
whilst those including only children at low-risk of PCHL were included.
Article selection, data extraction, and quality evaluation
One reviewer (EB) screened titles and abstracts of all identified reports against the inclusion
and exclusion criteria. A second reviewer (RK or CD) each reviewed a random 10% sample,
with inter-rater concordance assessed by calculation of the unweighted kappa statistic; discrep-
ancies were resolved by discussion. EB screened full reports against inclusion and exclusion
criteria; uncertainties were discussed with RK and CD.
Two reviewers (EB with either RK or CD) independently extracted data for each included
study using a form piloted on several studies before use (S2 File). Each study was classified into
one of four geographical regions based on included countries: Asia, Europe, North America,
and Australia. This form included questions regarding quality based on the JCIH guidelines
[1], Newcastle-Ottawa scale [14], STARD [15], and QUADAS-2 [16] criteria. Studies were
scored against eight quality criteria, with a maximum of nine points available (Table 1), as well
as by the original QUADAS-2 criteria. We resolved discrepancies by discussion. Study data
were collected and managed using REDCap (Research Electronic Data Capture), a web-based
application for data collection, hosted at University College London [17].
Statistical analysis plan
We included each study sample in analyses only once, thus multiple reports from single or
overlapping study populations were combined where possible; when indicated, the report pro-
viding most detail was used with related papers included as additional references.
Table 1. Quality scoring criteria.
Factor Score Scoring
PCHL definition 0 Not clearly defined—missing information on >1 feature (laterality, anatomy and
severity of study target condition)
1 Mostly defined—missing information on 1 feature
2 Clearly defined—specified all features
Other concerns 0 Further concern identified
1 No other concerns identified
Clear protocol 0 Not clearly defined–missing information on one or more features (which tests and
number of stages)
1 Clearly defined
Clear at-risk
protocol
0 Not clearly defined (how at-risk infants, as defined by the study, were managed)
1 Clearly defined
Sample bias 0 Any identified concerns
1 No identified concerns
UNHS coverage 0 <95% or unclear (# receiving�1 UNHS tests) / (target population)
1 �95%
UNHS follow-up 0 <70% or unclear (# not lost to follow-up by end of diagnostic tests) / (# failing first
stage of UNHS)
1 �70%
Overall follow-up 0 No follow-up after completion of relevant screening tests (screen negatives) or
diagnostic testing (screen positives)
1 Yes, some form of follow-up reported
PCHL: permanent childhood hearing loss; UNHS: universal newborn hearing screening.
https://doi.org/10.1371/journal.pone.0219600.t001
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We evaluated the characteristics of included studies. We calculated, for each study, the
prevalence and 95% confidence intervals (CI) of children with PCHL detected via UNHS and
fitting the review case definition in the screened population (defined as the number of children
receiving one or more screening tests). Pooled PCHL prevalence and 95% CIs were calculated
using the Freeman-Tukey double arc-sine transformation of proportions and Wilson (Score)
method [18]. Random-effects models using the Der Simonian and Laird method [19] were fit-
ted to account for the expected heterogeneity in the screened populations and screening meth-
ods used. Heterogeneity was evaluated with the I2 statistic (proportion of observed variance
not explained by chance) [20] and explored by stratifying prevalence calculations by study
characteristics. Sensitivity analyses were carried out excluding outliers and studies of low qual-
ity. Funnel plots and Egger’s test were used to assess small-sample bias, along with a sensitivity
analysis excluding studies with fewer than 7832 children (based on minimum sample size
required to accurately detect a prevalence of 1 per 1000 children within 95% CIs and a preci-
sion of 0.0005) [21]. Significance tests were conducted at 5% level.
Screening programme performance was assessed using available data on programme out-
comes, namely number of children with screen positive and negative results, and with (true
positives, false negatives) or without (false positives, true negatives) confirmed diagnoses.
Screen positives comprised all children referred to diagnostic testing, and screen negatives all
those not referred, regardless of attendance at diagnostic testing and attrition before the point
of diagnostic referral. True positives were defined as all screen-positive children diagnosed
with PCHL fitting the review case definition, whilst false positives were all screen-positive chil-
dren that did not have PCHL fitting the review case definition. We only calculated negative
predictive value (NPV), sensitivity and specificity for studies with follow-up to ascertain false
negatives (excluding unscreened children with PCHL, plus late-onset, acquired and progres-
sive PCHL from the false negative number where possible). Positive predictive value (PPV) cal-
culation was not limited by follow-up. Quantitative pooling of performance estimates was not
undertaken due to methodological differences between studies, such as tests used or diagnostic
referral criteria for testing.
PCHL prevalence by reported demographic and individual characteristics and in those with
or without NICU admission were explored and calculated where data were available. Analyses
were performed using STATA 15 (Stata Corp, College Station, TX).
Results
Selection of eligible studies
The literature search identified 6195 non-duplicate records, of which 5834 were excluded at
the title and abstract screen. A further 325 records were excluded after screening full texts. Five
relevant articles were identified from searches of the grey literature and references of included
papers. This resulted in 41 articles for inclusion in the meta-analysis, reporting on 32 separate
study populations (Fig 1). Two systematic reviews [9, 10] were included in the total number of
articles, however these were not included in data extraction as they contained no additional
data (all reviewed studies were already included as individual studies).
The summary unweighted inter-rater kappa statistic for abstract inclusion were 0.8 for EB
with both RK and CD, implying good agreement. Reviewers agreed the final list of eligible
studies by consensus, therefore inter-rater differences were not assessed.
Study characteristics
The characteristics of the included studies are described in Table 2, separately for those with
and without follow-up after screening and diagnostic testing was completed. Over 70% of
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included studies were from Europe (n = 23, 72%), with the remainder from North America
(n = 4, 13%), Australia (n = 3, 9%), or Asia (n = 2, 6%). Seven studies aimed to include out-of-
hospital births (i.e. were ‘population-based’), whilst 12 involved a single hospital, and 13 multi-
ple hospitals or birth centres. The Wessex study involved four hospitals that alternated UNHS
and non-UNHS screening periods; only data reported from UNHS screening periods are con-
sidered here.
Median study duration was 3 years (25th percentile [Q1]: 2, 75th percentile [Q3]: 6), with
included studies covering births between 1990 and 2014. Results from 1999 for the Mehl study
[50] are included as the numbers screened and diagnosed were unclear for other years.
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0219600.g001
Hearing loss prevalence detected by newborn screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0219600 July 11, 2019 6 / 21
Table 2. Included study characteristics.
Study authors Location Setting Period of
UNHS
UNHS
protocol
Reported PCHL
meeting review
case definition
Study
population,
n (%
screened)
PCHL
diagnoses via
UNHS, n
Follow-up after UNHS and
diagnostic testing
Studies with follow-up
Almenar
Latorre [22]
Spain 1 H Unclear OAE &
ABR
Bilateral >40 dB
HLa
1532 (n/a)e 4 Parent questionnaire at age 1 year
(n = 825, 53.8%, followed up)
Antoni [23] France 4 H 2005–2010 ABR Bilateral >35 dB
HLa
27885 (96.0) 30 Children with PCHL diagnoses via
UNHS had audiology records
checked (mean follow-up
length = 34 months, range 0–75
months)
Berninger [24] Sweden 2 H 1999–2004 OAE &
ABR
Bilateral SNHL,
CHL & mixed
>30 dB HLb
31092 (n/a)e 57 Clinician report of further cases
and acoustic amplification referral
database checked up to age 10
years
Calcutt [25] Australia P—1 region 2009–2011 ABR Bilateral SNHL
>40 dB HLb
185205
(94.9)
121 Targeted surveillance screen at
9–12 months (2606 attended of
4361 referred) and audiology
records checked up to age 4 years
Calevo [26] Italy 13 H/BC 2002–2004 OAE &
ABR
Bilateral >40 dB
HLa,b,c
32502 (99.2) 20 PCHL registry and audiology
records checked up to age 2 years
Cao-Nguyen
[27]
Switzerland 1 H 2000–2004 OAE &
ABR
Bilateral >40 dB
HLa,d
17535 (n/a)e 24 Audiology records checked to
unclear age (excluding late-onset
PCHL)
De Capua [28] Italy 3 H 1998–2007 OAE Bilateral SNHL,
CHL & mixed
>30 dB HLb
21125 (93.3) 24 Audiology records checked up to
age 1 year
Ng [29] Hong Kong 1 H 1999–1999 OAE Bilateral�40 dB
HLa,b
1076 (98.9) 3 Parent interviews at 18 and 36
months (n = 1020; 95.9% followed
up)
O’Connor [30] Ireland 6 H 2011–2012 OAE &
ABR
Bilateral SNHL,
CHL & mixed
>40 dB HLb,c
11763 (99.8) 12 Targeted surveillance screen up to
age 1 year
Watkin [31–
33]
UK P—1 region 1992–2002 OAE Bilateral�40 dB
HLa,b,c
35668 (94.9) 32 Audiology records checked up to
age 12 years (excluding late-onset
PCHL)
Wessex [34–36] UK 4 H—only
periods with
UNHS included
1993–1996 OAE &
ABR
Bilateral�40 dB
HLa
25609 (83.1) 22 Active follow-up and audiology,
healthcare and educational records
checked up to age 9 years
(excluding late-onset PCHL)
Studies without follow-up
Adelola [37] Ireland 2 H 2000–2007 OAE &
ABR
Bilateral >40 dB
HLa,b
26281 (97.9) 19
Aidan [38] France 1 H 1995–1997 OAE Bilateral SNHL
>40 dB HLb
1727 (82.3) 2
Bailey [39] Australia 5 H–excluding
some NICU
infants
2000–2001 OAE &
ABR
Bilateral >35 dB
HLa,b
13214 (96.2) 5
Caluraud [40] France 14 H/BC 1999–2011 OAE &
ABR
Bilateral >35 dB
HLa,d
101916
(99.8)
142
Fornoff [41] USA P—Statewide 2003–2004 OAE &
ABR
Bilateral SNHL,
CHL & mixed
�30 dB HLb
335412
(98.0)
160
Ghirri [42] Italy 1 H 2005–2009 OAE &
ABR
Bilateral >40 dB
HLa,b,c
8113 (n/a)e 21
(Continued)
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Table 2. (Continued)
Study authors Location Setting Period of
UNHS
UNHS
protocol
Reported PCHL
meeting review
case definition
Study
population,
n (%
screened)
PCHL
diagnoses via
UNHS, n
Follow-up after UNHS and
diagnostic testing
Gonzalez de
Aledo Linos
[43, 44]
Spain 2 H 2001–2003 OAE Bilateral SNHL
>40 dB HLb
8836 (98.4) 11
Guastini [45] Italy 1 H 2006–2009 OAE &
ABR
Bilateral >40 dB
HLa,b,d
8671 (n/a)e 2
Habib [46] Saudi
Arabia
1 H—excluding
children with
JCIH 1994 risk
factors
1996–2004 OAE Bilateral SNHL
�26 dB HLb
11986 (n/a)e 20
Magnani [47] Italy 1 H 2010–2013 OAE &
ABR
Bilateral SNHL
>40 dB HLb,c
11624 (99.7) 26
Martinez [48] Spain 1 H 2001–2002 OAE &
ABR
Bilateral >35 dB
HLa,b
1277 (94.2) 9
Mason [49] USA 1 H 1992–1997 ABR Bilateral SNHL,
CHL & mixed
>35 dB HLb
10773 (98.2) 16
Mehl [50] USA 57 H 1992–1999;
only 1999
included
ABR Bilateral SNHL,
CHL & mixed
�35 dB HLb
63590 (87.0) 63
Metzger [51] Switzerland 1 H—excluding
preterm births
2005–2010 OAE Bilateral�40 dB
HLa
12080 (n/a) 15
NSW [52] Australia P– 1 region 2003–2009 ABR Bilateral >40 dB
HLa,b
284694
(99.0)
283
Rohlfs [53] Germany 14 H/BC 2002–2006 OAE &
ABR
Bilateral�41 dB
HLa,b,c
65466 (92.8) 73
Uilenburg [54] Netherlands P—3 regions,
excluding NICU
infants
1999–2000 OAE Bilateral SNHL
�40 dB HLb
3336 (94.0) 1
Uus [55] UK 23 H 2001–2004 OAE &
ABR
Bilateral SNHL,
CHL & mixed
�40 dB HL
169487 (n/
a)e
169
Van der Ploeg
[56]
Netherlands P—entire
country,
excluding NICU
infants
2002–2009
(excluding
2007)
OAE &
ABR
Bilateral�40 dB
HLa,b
552820 (n/a) 427
Van
Kerschaver [6,
57, 58]
Belgium P—1 region 1999–2008 ABR Bilateral SNHL,
CHL & mixed
>40 dB HLb
628337
(95.9)
646
White [59] USA 1 H—random
sample
1990–1991 OAE &
ABR
Bilateral SNHL,
CHL & mixed
>25 dB HLb
1850 (n/a)e 6
aAnatomy of HL (CHL, SNHL, mixed) not specified.
bUnilateral loss also reported in study, but excluded in meta-analysis PCHL count.
cPCHL <40 dB HL also reported but <26 dB HL and 26–40 dB HL PCHL could not be separated.
dDiagnostic threshold unclear; assumed to be the same as the screening test threshold.
eUnclear study population considered; number given is those receiving�1 UNHS test.
ABR: auditory brainstem response; BC: birth clinic; CHL: conductive HL; dB HL: decibels hearing level; H: hospital; n/a: not applicable: NICU: neonatal intensive care
unit; OAE: otoacoustic emissions; P: population-based (including out of hospital births); PCHL: permanent childhood hearing loss; SNHL: sensorineural HL; UNHS:
universal newborn hearing screening.
https://doi.org/10.1371/journal.pone.0219600.t002
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Study population ranged between 1076 and 628337 (median 25945, Q1: 11198, Q3: 83691)
children for the 24 studies with this information available. Median study population recruit-
ment or screening coverage was 96.2% (Q1: 94.2, Q3: 98.9%) for 21 studies specifying both the
total study population and the number screened, with a total of 1799863 screened children in
the included studies.
UNHS screen protocol types were broadly grouped to: OAE-only (8 studies), ABR-only (6
studies), or OAE and ABR (18 studies), based on the screening tests used in the main study
protocol (S3 Table).
PCHL diagnoses
Between 1 and 646 children were diagnosed with PCHL fitting the review case definition via
UNHS in the individual studies. Most studies did not report follow-up after completion of
UNHS and diagnostic testing (n = 21). Of the 11 studies with any follow-up, nine attempted
to follow-up the entire study population, one only reported targeted surveillance results for
screen negative children with risk factors (O’Connor) [30] and one study only followed up
true positive children (Antoni) [23]. Thus there were 10 studies with follow-up of screen nega-
tive children. Methods of follow-up for screen negatives involved checking for PCHL diagno-
ses via local clinicians, audiology databases, registers or other records (n = 5), interviewing
parents (n = 2), targeted surveillance (n = 2; with one study also assessing audiology records),
and active testing along with checking for further diagnoses from multiple health, education
and audiology databases and staff involved in management of children with PCHL (n = 1)
(Table 2).
Study quality
The majority of studies were of high quality for the following criteria: clarity of PCHL case def-
inition, protocol details, clear description for management of at-risk children, lack of sample
bias, high UNHS coverage (�95%), and absence of other identified concerns. Lower or more
variable quality was seen for UNHS follow-up, as 15 studies did not clearly state the number
of children lost to follow-up during the UNHS and diagnostic testing stages. Additionally, few
studies reported any follow-up after screening and diagnostic testing was completed (Table 3;
Fig 2). Those with follow-up usually relied on passive methods, as described above, and rarely
reported whether screen-negative children with later diagnoses were failures of detection (false
negatives) or had late-onset, acquired or progressive PCHL. Results of QUADAS-2 scoring
(relating specifically to risk of bias) are presented in S3 File.
Prevalence
Pooled prevalence of UNHS-detected PCHL in the screened population was 1.1 (95% CI: 0.9,
1.3) per 1000 children (I2 = 89.2%) (Fig 3). Sensitivity analyses excluding studies with outlying
prevalences or of low quality[48], or those with identified sample bias [22–25, 35, 38, 39, 42,
46, 49, 53, 54, 59] did not alter prevalence estimates. Similarly, prevalence estimates using the
study population, rather than screened population, as the denominator did not affect estimates
(prevalence: 0.9, 95% CI: 0.8, 1.1 per 1000 children).
Funnel plot and Egger’s test results indicated that studies with smaller study populations
produced significantly larger prevalence estimates (Egger’s test p = 0.02). Studies based on sin-
gle hospitals had significantly smaller study populations and correspondingly higher PCHL
prevalence estimates than those based in multiple hospitals or population-based (heterogeneity
between settings, p = 0.003) (Fig 4). This association remained after exclusion of outliers [48],
and was not due to significant differences in measured quality indicators (including studies
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with sample bias, such as exclusion of high-risk children) or study characteristics. Excluding
studies with small study populations did not modify pooled prevalence estimates significantly.
Analyses of between-region heterogeneity revealed that prevalence estimates were signifi-
cantly smaller for studies carried out in Australia (heterogeneity between regions, p<0.001)
compared with other regions (Fig 4). Study characteristics or quality were similar between
regions with the exception of screening protocol type (Australian studies were significantly
more likely to use ABR than other protocols). Prevalence estimates did not vary significantly
Table 3. UNHS meta-analysis study quality scoring results.
Study PCHL
definition
Other
concerns
Clear
protocol
Clear at-risk
protocol
Sample bias UNHS
coverage
UNHS follow-
up
Overall follow-
up
De Capua 2 1 1 1 1 0 1 1
O’Connor 2 1 1 1 1 1 n/a 1
Calcutt 2 1 1 1 0 1 n/a 1
Calevo 0 1 1 1 1 1 1 1
Magnani 2 1 0 1 1 1 1 0
Mason 2 1 1 1 0 1 1 0
Ng 1 0 1 1 1 1 1 1
Caluraud 0 1 1 1 1 1 1 0
Guastini 1 1 1 1 1 n/a 1 0
Uilenburg 2 1 1 1 0 0 1 0
Uus 2 1 1 1 1 n/a n/a 0
White 2 1 1 1 0 n/a 1 0
Almenar Latorre 1 0 1 1 0 n/a 1 1
Gonzalez de Aledo
Linos
1 1 1 0 1 1 n/a 0
Habib 2 1 1 0 0 0 1 0
NSW 1 1 0 0 1 1 1 0
Van der Ploeg 1 1 1 1 0 1 n/a 0
Watkin 1 1 0 0 1 1 n/a 1
Wessex 1 1 1 1 0 0 n/a 1
Adelola 1 0 0 1 1 1 n/a 0
Antoni 1 0 0 0 0 1 1 1
Bailey 1 0 1 0 0 1 0 1
Cao-Nguyen 0 1 0 0 1 1 n/a 1
Ghirri 1 1 1 1 0 n/a n/a 0
Metzger 1 1 1 0 0 n/a 1 0
Berninger 2 0 0 0 0 n/a n/a 1
Fornoff 1 0 0 0 1 1 n/a 0
Martinez 1 1 0 0 1 0 n/a 0
Mehl 2 0 0 0 1 0 n/a 0
Rohlfs 0 1 1 1 0 0 0 0
Van Kerschaver 1 0 0 0 1 1 n/a 0
Aidan 0 1 1 0 0 0 0 0
Total high quality 11 high,
16 medium
23 21 18 17 17 15 11
Total low quality 5 9 11 14 15 8 2 21
Unclear n/a n/a n/a n/a n/a 7 15 n/a
n/a indicates unclear quality. PCHL: permanent childhood hearing loss; UNHS: universal newborn hearing screening.
https://doi.org/10.1371/journal.pone.0219600.t003
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by screening protocol type, year started, study duration, PCHL case definition, individual qual-
ity indicators. Lack of comparability between UNHS programme protocols (for example ages
of testing, number of tests, specific equipment, referral criteria) precluded investigation of
associations between these factors and PCHL prevalence.
Fig 2. Study quality indicators.
https://doi.org/10.1371/journal.pone.0219600.g002
Fig 3. UNHS-detected PCHL prevalence in the screened population.
https://doi.org/10.1371/journal.pone.0219600.g003
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Differences in prevalence by demographic and individual characteristics
Ethnic group of children with PCHL or of the study population was not reported in any study.
Sex distribution was reported for children with PCHL fitting the review case definition in
only two studies (44 and 57% female in the individual studies) [24, 55], however this was not
reported for the entire study population.
In three studies [30, 40, 59], information was provided on UNHS-detected PCHL preva-
lence by NICU admission status. Pooled PCHL prevalence was 5.9 (95% CI: 3.8, 8.4) per 1000
screened children admitted to NICU, compared with 0.8 (95% CI: 0.4, 1.4) per 1000 not admit-
ted: a PCHL prevalence rate ratio of 6.9 (95% CI: 3.8, 12.5) (Fig 5).
Screening programme performance
Screening programme coverage and yield is presented in Table 2 and Fig 3. In the 25 studies
with available information, PPV ranged from 2% to 84% (Table 4). A median of 93% (Q1:
86%, Q3: 100%) of screen positive children attended diagnostic testing in 21 studies reporting
this information.
The Wessex study was deemed to have highest quality follow-up after UNHS and diagnostic
testing, with active and passive follow-up to age 9 years, using multiple sources and excluding
acquired, late-onset, or progressive PCHL. Sensitivity and specificity for this study were 92%
(95% CI: 74%, 98%) and 98% (95% CI: 98%, 98%), respectively. NPV was 100% (95% CI:
100%, 100%). The remaining nine studies used less robust methods to follow-up screen
negatives, as described earlier, however they reported similar screen performance measures
to the Wessex study; overall NPV was 100% in the seven studies with available information,
Fig 4. UNHS-detected PCHL prevalence in the screened population by regional and setting subgroups.
https://doi.org/10.1371/journal.pone.0219600.g004
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sensitivity 89–100% (for eight studies) and specificity 92–100% (for seven studies) (Table 5).
Only 4 studies reported loss to follow-up of children in the screen negative group; this was
�2%.
Discussion
Key findings
We estimate that UNHS programmes in VHD countries identify PCHL in 1 out of every 1000
children screened. This was lower in studies carried out in Australia and higher in studies car-
ried out in single hospitals, which included smaller study populations relative to population-
based studies or those based on several hospitals. The highest prevalence was found in infants
admitted to NICU, a group known to be at higher risk of PCHL, compared with those who
were not. No studies reported ethnic group and only two studies reported sex, precluding esti-
mation of sex- or ethnic-specific pooled prevalences.
Analysis of screening programme performance demonstrated good population coverage
with high detection rates, however PPV varied widely across studies. Although NPV, sensitiv-
ity and specificity appeared high, these could only be estimated from studies with follow-up of
screen negatives, which had marked variation in methods for, and completeness of, follow-up.
Strengths and limitations
Strengths of this systematic review and meta-analysis include prospective publication of our
protocol on PROSPERO, the systematic search strategy employed, as well as the inclusion of
unpublished literature and articles in all languages, which reduced likelihood of inclusion bias.
Independent article selection, data extraction, and quality assessment by multiple reviewers
reduced risk of bias or error. Finally, we used robust statistical methods, including random-
effects models, to calculate prevalence, screening programme performance and to examine
heterogeneity.
Our searches were not restricted by language and included unpublished literature, includ-
ing UNHS programme reports and evaluations, however we cannot exclude the possibility
Fig 5. UNHS-detected PCHL prevalence in NICU versus non-NICU populations.
https://doi.org/10.1371/journal.pone.0219600.g005
Hearing loss prevalence detected by newborn screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0219600 July 11, 2019 13 / 21
Table 4. Positive predictive values for UNHS studies.
Study authors Criteria for diagnostic referral Referral of bilateral only (Bi), or both unilateral and
bilateral (Bo), failure?
SP, n TP, n PPV, %
95% CI
OAE only
Uilenburg OAE failure Bo 69 1 1.5
0.3–7.8
De Capua OAE failure or presence of risk factors Bo 1536 24 1.6
1.1–2.3
Gonza´lez de Aledo
Linos
OAE failure or presence of risk factors Bo 342 11 3.2
1.8–5.7
Metzger OAE failure Bi 253 15 5.9
3.6–9.6
Habib OAE failure Bo 300 20 6.7
4.4–10.1
Ng OAE failure at 40 dB HL Bo 37 3 8.1
2.8–21.3
Aidan OAE failure NS 9 2 22.2
6.3–54.7
ABR only
Mehl ABR failure (or OAE in few hospitals) Bo 1283 63 4.9
3.9–6.2
Calcutt ABR failure or presence of risk factors Bo 1633 121 7.4
6.2–8.8
Antoni ABR failure at 30 dB HL (modified in 2009 to only
bilateral failures)
Bo 226 30 13.3
9.5–18.3
Van Kerschaver ABR failure at 35 dB HL Bo 2316 646 27.9
26.1–
29.8
OAE & ABR
O’Connor ABR failure Bo 525 12 2.3
1.3–4.0
White ABR failure at 30 dB HL Bo 115 6 5.2
2.4–10.9
Wessex ABR failure at 35 dB HL (modified Oct 1994 to only
bilateral)
Bo 392 22 5.6
3.7–8.4
Fornoff Failure of last screening test (OAE or ABR) Bo 2135 160 7.5
6.5–8.7
Magnani ABR failure Bo 241 26 10.8
7.5–15.3
Martı´nez OAE failure or presence of risk factors Bo 69 9 13.0
7.0–23.0
Adelola ABR failure Bo 92 19 20.7
13.6–
30.0
Bailey ABR failure at 35 dB HL Bo 23 5 21.7
9.7–41.9
Ghirri ABR failure Bo 84 21 25.0
17.0–
35.2
Guastini ABR failure at 40 dB HL Bo 6 2 33.3
9.7–70.0
Rohlfs ABR failure at 35 dB HL Bo 217 73 33.6
27.7–
40.2
(Continued)
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that we failed to identify relevant unpublished evidence. Our findings are generalisable to
VHD countries only, reflecting the selection criteria employed, and we cannot assume they
apply to other settings. Our analyses were constrained by the limited reporting of demographic
and individual characteristics including on sex, ethnic group and age at diagnosis, loss to fol-
low-up of those with screen positive results, as well as lack of reporting on follow-up (active or
passive) with which to identify children diagnosed at older ages. Later PCHL diagnoses may
reflect failures of screening, diagnosis, or management, or variation in natural history resulting
in PCHL of progressive or later onset. Few studies employed high-quality active ascertainment
of later diagnoses limiting the studies available for estimating NPV, sensitivity, and specificity.
Table 4. (Continued)
Study authors Criteria for diagnostic referral Referral of bilateral only (Bi), or both unilateral and
bilateral (Bo), failure?
SP, n TP, n PPV, %
95% CI
Almenar Latorre ABR failure at 40 dB HL Bo 11 4 36.4
15.2–
64.6
Calevo ABR failure Bo 41 20 48.8
34.3–
63.5
Caluraud ABR failure at 35 dB HL Bo 170 142 83.5
77.2–
88.4
ABR: auditory brainstem responses test; NS: not stated; OAE: otoacoustic emissions test; PPV: positive predictive value; SP: screen positives; TP: true positives; UNHS:
universal newborn hearing screening.
https://doi.org/10.1371/journal.pone.0219600.t004
Table 5. Negative predictive value, sensitivity, and specificity for studies with follow-up.
Study authors SP, n TP, n SN, n FN, n NPV, %
95% CI
Sensitivity, %
95% CI
Specificity, %
95% CI
Almenar Latorre 11 4 1521 0 100.0
99.9–100.0
100.0
51.0–100.0
99.5
99.6–99.8
Berninger n/a 57 n/a 0 n/a 100.0
93.7–100.0
n/a
Calcutt 1633 121 174187 10 100.0
100.0–100.0
92.4
86.5–95.8
99.1
99.1–99.2
Calevo 41 20 32217 0 100.0
100.0–100.0
100.0
83.9–100.0
99.9
99.9–100.0
Cao-Nguyen n/a 24 n/a 2 n/a 92.3
75.9–97.9
n/a
De Capua 1536 24 18164 1 100.0
100.0–100.0
96.0
80.5–99.3
92.3
91.9–92.7
Ng 37 3 1027 0 100.0
99.6–100.0
100.0
43.9–100.0
96.8
95.6–97.7
O’Connor 525 12 11213 1 100.0
100.0–100.0
92.3
66.7–98.6
95.6
95.2–96.0
Watkin n/a 32 n/a 4 n/a 88.9
74.7–95.6
n/a
Wessex 392 22 20887 2 100.0
100.0–100.0
91.7
74.2–97.7
98.3
98.1–98.4
CI: confidence intervals; FN: false negatives; n/a: not given or could not be calculated; NPV: negative predictive value: SN: screen negatives; SP: screen positives; TP: true
positive
https://doi.org/10.1371/journal.pone.0219600.t005
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We were unable to assess bias due to selective attrition in screen performance estimates as this
was rarely reported; however the consistently reported high attendance at diagnostic testing
reduced the likelihood of bias in PPV estimates.
Interpretation
Our pooled estimate of PCHL prevalence of around 1 per 1000 children is consistent with that
reported from existing studies of congenital PCHL prevalence [60] prior to UNHS, suggesting
that UNHS detects most newborns with early-onset PCHL. We did not detect differences in
UNHS-detected PCHL prevalence by study date or target PCHL definition. There was also no
association between screening protocol type and detected prevalence. This is consistent with at
least one previous study comparing an OAE-only versus ABR-only protocol [61] and indicates
that reported variation in referral rates by protocol type has little impact on detected preva-
lence [62]. Protocol type may influence programme performance and cost-effectiveness, how-
ever, further research is required to explore this. We found a higher prevalence of PCHL in
studies reporting the experience of single hospitals, in comparison to those based on multiple
hospitals or whole populations. The single hospital studies tended to have smaller samples
than the other setting types. The difference in prevalence by settings or sample size was not
clearly attributable to the measured quality indicators, including risk of sample bias, or other
study characteristics. It may be that unmeasured differences in the study populations explain
this finding, for instance differences in the NICU population size and characteristics.
Demographic factors, such as sex and ethnicity, which may provide insights into potential
causal mechanisms, were largely not reported. This restricted exploration of variations in prev-
alence by these characteristics, and might have resulted in the large I2 value. In particular, we
were unable to examine whether ethnic variation explained regional variations in prevalence.
For example, Martı´nez et al suggested that the high prevalence in their study may reflect the
high proportion of children of Roma ethnic origin in their study population [48]. Although
there is no evidence that children of Roma ethnicity are at higher risk of PCHL, two studies
have suggested other ethnic differences in hearing loss [63, 64]. The small number of studies in
regions other than Europe may have reduced statistical power to detect regional differences in
prevalence.
Prevalence of PCHL in babies admitted to NICU was almost seven times higher than for
those not admitted. This is consistent with our previous finding based on a UK-wide cohort
study whereby NICU or special care baby unit admission was associated with 6.3 (95% CI: 2.3,
17.6) times higher risk of PCHL, and neonatal illness without NICU admission with 2.6 (95%
CI: 1.2, 6.0) times higher risk, than children with no neonatal illness [65]. The association
between NICU and high PCHL risk may result from the underlying cause of PCHL, for exam-
ple craniofacial anomalies or other syndromal pathologies, as well as exposure to ototoxic anti-
biotics, prolonged mechanical ventilation and asphyxia, hyperbilirubinaemia, and high noise
levels in NICU [1, 4, 66, 67].
UNHS programme screening, diagnostic, and follow-up protocols varied greatly across
studies. We therefore did not combine PPV estimates due to differences in screening equip-
ment, testing protocol (including choice of stages and number of repeats), tester training,
referral criteria and age at testing [68–71]. NPV, sensitivity and specificity are also affected by
these factors, as well as by the strategies employed to ascertain children with later PCHL diag-
noses and false negatives. PPV varied widely between studies whilst NPV, sensitivity and speci-
ficity estimates were reasonably consistent where they could be calculated. This reinforces
findings from a previous review suggesting that guidelines to ensure standardised, high quality
public reporting of UNHS programme performance are required [10]. Further evaluation,
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using adequate follow-up to detect false negatives, is justified to inform improvements in the
quality and performance of screening programmes. Adequate follow-up should also involve
assessing hearing threshold changes in children diagnosed with PCHL, as these can fluctuate
or normalise over time [23, 24], reflecting the difficulty in conclusively diagnosing PCHL in
very young children [72].
Conclusions
We estimate that in VHD countries, audiological and other services will be required for around
1 per 1000 children with PCHL following UNHS screening, however this may vary depending
on the proportion of children admitted to NICU, in whom PCHL prevalence is much greater.
Future research to investigate differences in PCHL prevalence by sex and ethnicity is required,
and to compare the performance of different screening protocols to identify those that are
most effective. Both will depend on the quality of data collection and reporting, including attri-
tion, and implementation of active follow-up measures to ascertain false negatives.
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